PURPOSE OF REVIEW: Cutaneous T-cell lymphomas (CTCLs) are a heterogenous group of non-Hodgkin's lymphomas characterized by atypical, skin-homing T lymphocytes and have varying prognoses depending on subtype and disease stage. Numerous therapeutic options exist; however, many patients experience refractory disease and novel treatments are needed. RECENT FINDINGS: This review will highlight selected advances in CTCL treatment over the past year (2007-2008). Discoveries regarding the pathophysiology of mycosis fungoides and Sézary syndrome, the two most common CTCL types, have led to an expansion of new treatments and an increase in experience with multimodality therapy continues to increase. A number of reports have examined both combination regimens of currently available CTCL therapies as well as treatments approved for other dermatologic or oncologic conditions. Also, several novel skin-directed treatments and systemic compounds have been studied in all CTCL stages as well as in treatment-refractory disease. SUMMARY: There remains a continued impetus to develop and amass experience with new therapeutic options for CTCL, particularly for patients with advanced stage and treatment-refractory disease.
PURPOSE OF REVIEW: Cutaneous T-cell lymphomas (CTCLs) are a heterogenous group of non-Hodgkin's lymphomas characterized by atypical, skin-homing T lymphocytes and have varying prognoses depending on subtype and disease stage. Numerous therapeutic options exist; however, many patients experience refractory disease and novel treatments are needed. RECENT FINDINGS: This review will highlight selected advances in CTCL treatment over the past year (2007-2008). Discoveries regarding the pathophysiology of mycosis fungoides and Sézary syndrome, the two most common CTCL types, have led to an expansion of new treatments and an increase in experience with multimodality therapy continues to increase. A number of reports have examined both combination regimens of currently available CTCL therapies as well as treatments approved for other dermatologic or oncologic conditions. Also, several novel skin-directed treatments and systemic compounds have been studied in all CTCL stages as well as in treatment-refractory disease. SUMMARY: There remains a continued impetus to develop and amass experience with new therapeutic options for CTCL, particularly for patients with advanced stage and treatment-refractory disease.
Authors: Maria Wysocka; Noor Dawany; Bernice Benoit; Andrew V Kossenkov; Andrea B Troxel; Joel M Gelfand; Michael Kelly Sell; Louise C Showe; Alain H Rook Journal: Leuk Lymphoma Date: 2011-10
Authors: Rachael A Clark; Jeffrey B Shackelton; Rei Watanabe; Adam Calarese; Kei-ichi Yamanaka; James J Campbell; Jessica E Teague; Helen P Kuo; DirkJan Hijnen; Thomas S Kupper Journal: Blood Date: 2010-12-09 Impact factor: 22.113
Authors: Jasmine Zain; Joycelynne M Palmer; Maria Delioukina; Sandra Thomas; Ni-Chun Tsai; Auayporn Nademanee; Leslie Popplewell; Karl Gaal; David Senitzer; Neil Kogut; Margaret O'Donnell; Stephen J Forman Journal: Leuk Lymphoma Date: 2011-06-24
Authors: Alfonso Dueñas-Gonzalez; Maria Teresa Vega; Déborah Martinez-Baños; Linda García-Hidalgo; Pedro Sobrevilla Journal: Case Rep Med Date: 2010-03-21
Authors: Max Schlaak; Juliane Pickenhain; Sebastian Theurich; Nicole Skoetz; Michael von Bergwelt-Baildon; Peter Kurschat Journal: Cochrane Database Syst Rev Date: 2013-08-29
Authors: V R Paralkar; S D Nasta; K Morrissey; J Smith; P Vassilev; M E Martin; S C Goldstein; A Loren; A H Rook; E J Kim; D L Porter Journal: Bone Marrow Transplant Date: 2011-10-24 Impact factor: 5.483
Authors: Andreas Willerslev-Olsen; Thorbjørn Krejsgaard; Lise M Lindahl; Charlotte Menne Bonefeld; Mariusz A Wasik; Sergei B Koralov; Carsten Geisler; Mogens Kilian; Lars Iversen; Anders Woetmann; Niels Odum Journal: Toxins (Basel) Date: 2013-08-14 Impact factor: 4.546